Comparison of subscription access and open access obstetrics and gynecology journals in the SCImago database

Objectives:  The aim of this study is to compare the annual SJR and to evaluate the other parameters that show the scientific effect of journals in terms of open access (OA) or subscription access (SA) in the field of obstetrics and gynecology according to the SCImago database. Material and methods: This study was conducted between September-December 2019 at Near East University. The SCImago Journal & Country Rank database was used to collect information about the journals. We evaluated and compared the changes in the one-year SJR (SCImago Journal Rank) and journal impact factor (JIF) of OA and SA journals. Results: Data from 183 scientific journals in the field of obstetrics and gynecology from the period between 1999 and 2018 were evaluated, where 140 of these journals were SA and 43 were OA. The average SJR of OA journals in 1999 was 0.17, while it was 0.38 for SA journals. In 2018, these values were 0.31 and 0.78 for OA and SA journals, respectively. In the comparison of JIF, the average of the OA journals in 1999 was 0.09, while it was 0.66 for SA journals. In 2018, these values were 0.80 and 1.93 for OA and SA journals, respectively. Conclusions: Access to information has become easier due to technological developments and this will continue to affect the access policies of journals. Despite the disadvantages of predator journals, the rise of OA journals in terms of number and quality is likely to continue

Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women

Recently, myoinositol (myo-ins) and folic acid combination has gained an important role for treating Polycystic Ovary Syndrome (PCOS), in addition to combined oral contraceptives (COC). We aimed to examine myo-ins effects on anti-Mullerian hormone (AMH) levels and compare them with those ones obtained administering COC. In this prospective study, 137 PCOS patients, diagnosed according to Rotterdam criteria and admitted to the Reproductive Endocrinology and Infertility Outpatient Clinic at Dokuz Eylul University (Izmir, Turkey), were included. After randomization to COC (n=60) and myo-ins (n=77) arms, anthropometric measurements, blood pressure, Modified Ferriman Gallwey scores were calculated. Biochemical and hormonal analysis were performed, and LH/FSH and Apo B/A1 ratios were calculated. Data analysis was carried out in demographically and clinically matched 106 patients (COC = 54; myo-ins = 52). After 3-month treatment, increase in HDL and decreases in LH and LH/FSH ratio were statistically more significant only in COC group when compared with baseline (in both cases p>0.05). In myo-ins group, fasting glucose, LDL, DHEAS, total cholesterol, and prolactin levels decreased significantly (for all p<0.05). Progesterone and AMH levels, ovarian volume, ovarian antral follicle, and total antral follicle counts lessened significantly in both groups (for all p<0.05). In PCOS treatment, MYO is observed more effective in reductions of total ovarian volume and AMH levels

The importance of inflammation markers in polycystic ovary syndrome

OBJECTIVE: This study aimed to examine inflammation markers in patients with polycystic ovary syndrome (PCOS) and to compare them with healthy women

Smoking reduces ovarian stromal blood flow in polycystic ovary syndrome patients

Objectives: The objective of the current research is to compare hormonal, metabolic and ovarian stromal blood flow outcomes in smoking versus non-smoking polycystic ovary syndrome (PCOS) patients

Comparison of Anti-mullerian Hormone (AMH) and Hormonal Assays for Phenotypic Classification of Polycystic Ovary Syndrome

Objectives: The aim is to compare the hormonal status and anti-mullerian hormone (AMH) levels of patients who have different polycystic ovary syndrome (PCOS) phenotypes, polycystic ovarian morphology (PCOM) and healthy women

Bone Mineral Density and Lipid Metabolism After Alendronate and Strontium Ranelate Treatment

BACKGROUND/AIM

The effect of myoinositol on ovarian blood flows in women with polycystic ovary syndrome

To evaluate whether 4 gram myoinositol and 400 mcg folic acid(MYO) therapy has any effects on ovarian stromal blood flow by using pulsed and color Doppler at 3 months follow-up period in polycystic ovary syndrome (PCOS). One-hundred eighty patients were designed into six groups; Group 1: PCOS patients that received OCP containing 30 mcg ethinyl estradiol (EE) plus 3 mg drospirenone (DRP); Group 2: PCOS patients that received MYO; Group 3: PCOS patients that received no medication. Group 4: Healthy patients that received OCP; Group 5: Healthy patients that received MYO; Group 6: Healthy patients that received no medication. Resistance index (RI) and pulsatility index (PI) of both ovaries were assessed. There was a significant increase in RI and PI of both ovarian stromal blood flow women with PCOS who received OCP (Group 1, p < .001) and MYO (Group 2, p < .001). The rate of increment in both RI and PI values were similar for OCP users (Group 1) and MYO users(Group2) in PCOS patients. MYO therapy reduced ovarian vascularization in both PCOS and healthy users after 3 months and this decrease is especially noticeable in women with PCOS compared to healthy women. OCP therapy also reduced ovarian vascularization just like MYO therapy

Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial

Objectve: The aim of the study is to investigate the effect of myo-inositol (MYO) on pregnancy rates of patients diagnosed with polycystic ovary syndrome (PCOS) who undergone controlled ovulation induction and intrauterine insemination (IUI).Methods: A total of 196 infertile patients diagnosed with PCOS and admitted to Dokuz Eylul University Faculty of Medicine were included in the study between March 2013 and May 2016. The patients in group 1 (n=98) were given 4g MYO and 400g folic acid before and during ovulation induction. The patients undergone controlled ovarian hyperstimulation (COH) with recombinant FSH and IUI. The patients in group 2 (n=98), were given recombinant FSH directly and 400g folic acid. The primary outcome measure of this study was the clinical pregnancy rate.Results: In group 1, 9 patients conceived spontaneous pregnancy. During COH+IUI treatment three cycles were canceled in group 1 and 8 cycles in group 2. Total rFSH dose and cycle duration were significantly lower and clinical pregnancy rates were higher in group 1. The pregnancy rate for group 1 was %18.6 and for group 2 was %12.2.Conclusons: This study shows that MYO should be considered in the treatment of infertile PCOS patients. MYO administration increases clinical pregnancy rates, lowers total rFSH dose and the duration of the ovulation induction